SETDB1 and Huntington disease: Pharmacological treatment with small molecules such as mithramycin, cystamine and nogalamycin reduced the level of H3K9me3 and the associated methyltransferase protein SETDB1, which improved behavior and neuropathological phenotype in HD transgenic mice [10,11,12].